ABSTRACT
Background The majority of Plasmodium falciparum malaria diagnoses in Africa are made using rapid diagnostic tests (RDTs) that detect histidine-rich protein 2. Increasing reports of false-negative RDT results due to parasites with deletions of the pfhrp2 and/or pfhrp3 genes (pfhrp2/3) raise concern about existing malaria diagnostic strategies. We previously identified pfhrp2-negative parasites among asymptomatic children in the Democratic Republic of the Congo (DRC), but their impact on diagnosis of symptomatic malaria is unknown.
Methods We performed a cross-sectional study of false-negative RDTs in symptomatic subjects in 2017. Parasites were characterized by microscopy; RDT; pfhrp2/3 genotyping and species-specific PCR assays; a multiplex bead-based immunoassay; and/or whole-genome sequencing.
Results Among 3,627 symptomatic subjects, we identified 427 (11.8%) RDT-/microscopy+ cases. Parasites from eight (0.2%) samples were initially classified as putative pfhrp2/3 deletions by PCR, but antigen testing and whole-genome sequencing confirmed the presence of intact genes. Malaria prevalence was high (57%) and non-falciparum co-infection common (15%). HRP2-based RDT performance was satisfactory and superior to microscopy.
Conclusions Symptomatic malaria due to pfhrp2/3-deleted P. falciparum was not observed in the DRC.
Ongoing HRP2-based RDT use is appropriate for the detection of falciparum malaria in the DRC.
Competing Interest Statement
JBP reports support from the World Health Organization related to the scope of the present study and non-financial support from Abbott Laboratories, outside the scope of the present study. All other authors declare no conflicts of interest.
Funding Statement
This work was supported by the Global Fund to Fight AIDS, Tuberculosis, and Malaria. It was also partially supported by awards from the National Institutes of Allergy and Infectious Diseases [R01AI132547 to JBP and JJJ] and the Doris Duke Charitable Foundation to JBP.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethical Committee of the Kinshasa School of Public Health. Analysis of de-identified samples and data was deemed non-human subjects research by the University of North Carolina Institutional Review Board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data not contained in the manuscript or supplements is available upon reasonable request.
